Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

autologous tumor-specific antigen-loaded dendritic cells

A cell-based cancer vaccine composed of autologous dendritic cells (DCs) loaded with tumor-specific antigen(s) (TSAs), with potential immunostimulatory and antineoplastic activities. Upon administration of the autologous TSA-loaded DCs, the DCs stimulate a specific cytotoxic T-lymphocyte (CTL)-mediated immune response against the tumor cells expressing the TSA(s), resulting in tumor cell lysis.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	autologous TSA-DC autologous TSA-DC vaccine autologous TSA-DCs autologous TSA-loaded dendritic cells tumor specific antigen-loaded autologous dendritic cells

autologous tumor-specific antigen-loaded dendritic cells

Search NCI's Drug Dictionary